Brivaracetam
- Brivaracetam
- 357336-20-0
- Briviact
- UCB 34714
- UCB-34714
- Create:2006-10-25
- Modify:2025-02-01
- (2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide
- 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-
- 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
- brivaracetam
- Briviact
- UCB 34714
- UCB-34714
- UCB34714
- Brivaracetam
- 357336-20-0
- Briviact
- UCB 34714
- UCB-34714
- 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide
- UCB34714
- (2s)-2-[(4r)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
- compound 83alpha
- UNII-U863JGG2IA
- U863JGG2IA
- 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-
- CHEBI:133013
- BRIVARACETAM (MART.)
- BRIVARACETAM [MART.]
- (2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide
- Rikelta
- (2S)-2-((4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL) BUTANAMIDE
- Brivaracetam [USAN:INN]
- brivaracetamum
- Brivaracetam?
- (2S)-2-[(4R)-2-oxidanylidene-4-propyl-pyrrolidin-1-yl]butanamide
- (R)-Atomoxetine
- Briviact (TN)
- 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-; (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide; Brivaracetam; Briviact; UCB 34714
- MFCD25976668
- BRIVARACETAM [MI]
- BRIVARACETAM [INN]
- BRIVARACETAM [JAN]
- BRIVARACETAM [USAN]
- BRIVARACETAM [WHO-DD]
- SCHEMBL122081
- Brivaracetam (JAN/USAN/INN)
- CHEMBL607400
- GTPL9041
- AE5 - Anti-epileptic drugs 5
- DTXSID00905081
- N03AX23
- MSYKRHVOOPPJKU-BDAKNGLRSA-N
- BRIVARACETAM [ORANGE BOOK]
- GLXC-27574
- EX-A2748
- BDBM50422531
- AKOS027324306
- CCG-266666
- CS-3418
- DB05541
- NCGC00390779-02
- AC-29289
- AS-35277
- BB161996
- HY-14449
- NS00068020
- D08879
- Q408099
- BRD-K00634421-001-01-0
- (S)-2-((R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide
- (2S)-2-((4R)-2-oxo-4-n-propyl-1-pyrrolidinyl)butanamide
- 1-PYRROLIDINEACETAMIDE, alpha-ETHYL-2-OXO-4-PROPYL (alphaS,4R)-
- 1-PYRROLIDINEACETAMIDE, .ALPHA.-ETHYL-2-OXO-4-PROPYL (.ALPHA.S,4R)-
P264, P270, P301+P317, P330, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Prospective studies reported that chronic brivaracetam therapy was not accompanied by significant elevations in serum aminotransferase levels and clinically apparent liver injury was not observed. Brivaracetam has had limited general use, but has not been linked to instances of clinically apparent liver injury. Levetiracetam, an anticonvulsant with similar structure and mechanism of action, has been linked to rare instances of acute liver injury, generally arising within 1 to 20 weeks and presenting with a hepatocellular pattern of injury without immunoallergic or autoimmune features. Whether similar cases will be linked to brivaracetam is not known.
Likelihood score: E (unlikely cause of clinically apparent liver injury).
◉ Summary of Use during Lactation
Limited information on use of brivaracetam during breastfeeding indicates that infants might have serum levels in the therapeutic range with exclusive breastfeeding, but undetectable levels with partial breastfeeding. If brivaracetam is required by the mother, it is not necessarily a reason to discontinue breastfeeding, but monitor the infant for drowsiness, agitation, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of drugs. Measurement of infant serum levels may help rule out toxicity if there is a concern.
◉ Effects in Breastfed Infants
Three infants, including one pair of twins, were breastfed while their mothers were taking brivaracetam. The twins were partially breastfed twice daily by a mother taking only brivaracetam and the other infant was exclusively breastfed by a mother taking brivaracetam, lacosamide and perampanel for 6 weeks, then partially breastfed. None of the infants exhibited reduced wakefulness or feeding problems. At one year of age, the mothers reported normal development.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=MSYKRHVOOPPJKU-BDAKNGLRSA-N
- Avoid alcohol. Taking Brivaracetam with alcohol may increase alcohol's effects on attention, memory, and psychomotor functioning.
- Take with or without food.
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusBrivaracetam [USAN:INN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0357336200ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useBrivaracetamhttps://www.drugbank.ca/drugs/DB05541
- EPA DSSToxBrivaracetamhttps://comptox.epa.gov/dashboard/DTXSID00905081CompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-notice(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanamidehttps://echa.europa.eu/substance-information/-/substanceinfo/100.118.642(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide (EC: 801-184-2)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/61700
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- ChEBI
- Drug Enforcement Administration (DEA)LICENSEUnless otherwise indicated, information on Department of Justice websites is in the public domain and may be copied and distributed without permission. Citation of the Department of Justice as source of the information is appreciated, as appropriate.https://www.justice.gov/legalpoliciesBrivaracetamhttps://www.deadiversion.usdoj.gov/schedules/DEA drug and chemical classificationhttps://www.dea.gov/drug-information/drug-scheduling
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- LiverTox
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- Comparative Toxicogenomics Database (CTD)LICENSEIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.http://ctdbase.org/about/legal.jsp
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsBRIVARACETAMhttps://www.dgidb.org/drugs/rxcui:1739745
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)Brivaracetamhttps://idrblab.net/ttd/data/drug/details/D0CT4D
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Crystallography Open Database (COD)LICENSEAll data in the COD and the database itself are dedicated to the public domain and licensed under the CC0 License. Users of the data should acknowledge the original authors of the structural data.https://creativecommons.org/publicdomain/zero/1.0/
- DailyMed
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/legal-noticeBriviact (in Italy: Nubriveo) (EMEA/H/C/003898)https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveoBrivaracetam (P/0174/2021)https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000332-pip01-08-m16Brivaracetam (P/0003/2022)https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000332-pip02-17-m03Brivaracetam (P/0324/2020)https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000332-pip01-08-m15
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- EU Clinical Trials Register
- FDA Orange BookLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/BrivaracetamNORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/Brivaracetamhttps://www.whocc.no/atc_ddd_index/?code=N03AX23
- FDA Medication GuidesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingBRIVIACThttps://dps.fda.gov/medguide
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlTherapeutic category of drugs in Japanhttp://www.genome.jp/kegg-bin/get_htext?br08301.kegUSP drug classificationhttp://www.genome.jp/kegg-bin/get_htext?br08302.kegAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.keg
- Metabolomics Workbench
- NIPH Clinical Trials Search of Japan
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlbrivaracetamhttps://rxnav.nlm.nih.gov/id/rxnorm/1739745
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policiesbrivaracetamhttps://www.pharmgkb.org/chemical/PA166153491
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/aboutbrivaracetamhttps://pharos.nih.gov/ligands/BRWYT3F6AUL5
- RCSB Protein Data Bank (RCSB PDB)LICENSEData files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.https://www.rcsb.org/pages/policies
- SpectraBaseBrivaracetamhttps://spectrabase.com/spectrum/E2234k29uiRBrivaracetamhttps://spectrabase.com/spectrum/Ck9XodQIsPKBrivaracetamhttps://spectrabase.com/spectrum/IEKZy3k8jIi
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- Wikidatabrivaracetamhttps://www.wikidata.org/wiki/Q408099
- WikipediaBrivaracetamhttps://en.wikipedia.org/wiki/Brivaracetam
- Wiley
- PubChem
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlbrivaracetamhttps://www.ncbi.nlm.nih.gov/mesh/67482793Anticonvulsantshttps://www.ncbi.nlm.nih.gov/mesh/68000927
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 404036144https://pubchem.ncbi.nlm.nih.gov/substance/404036144
- NCBI